Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome With Early Treatment
By F. Weidemann, M. Niemann, F. Breunig, S. Herrmann, M. Beer, S. Störk, W. Voelker, G. Ertl, C. Wanner, J. Strotmann. 2009
476 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology, Physiology
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Physiology
Citations in the corpus
- Fabry disease (2010, background): “Of note, the largest decreases in LVM were observed in patients with the greatest degree of hypertrophy at baseline [330], a result that contrasts with those from a number of studies with agalsidase beta [20,91,338,352].”